论文部分内容阅读
目的:观察东菱克栓酶(DF-521)与低分子肝素(LMWH)联合治疗急性脑梗塞的临床疗效及安全性。方法:将符合治疗时间窗的急性脑梗塞115例病人随机分为4组:东菱克栓酶与低分子肝素组、东菱克栓酶组、低分子肝素组、对照组用低分子右旋糖酐,4组均采用复方丹参加包二磷胆碱作为基础治疗。结果:东菱克栓酶加用低分子肝素组疗效优于二者单用,前三组临床疗效优于对照组。且在治疗中没有发生出血等副作用而停用。结论:东菱克栓酶与低分子肝素联合治疗急性脑梗死临床疗效优于单独使用,安全可靠。
Objective: To observe the curative effect and safety of combination of DF-521 with low molecular weight heparin (LMWH) in the treatment of acute cerebral infarction. Methods: One hundred and fifteen patients with acute cerebral infarction meeting the treatment time window were randomly divided into four groups: tachykinase and low molecular weight heparin group, glibenclamide group, low molecular weight heparin group, low molecular weight dextran, 4 groups were treated with compound Danshen plus diphosphocholine as the basic treatment. Results: Batroxobin with low molecular weight heparin group was superior to the two alone, the first three groups were better than the control group. And in the treatment of bleeding and other side effects and disabled. Conclusion: It is safe and reliable to treat the acute cerebral infarction with combination of rhodanine and low molecular weight heparin.